Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
trial safety
Biotech
Ultragenyx granted go-ahead to up doses for Angelman therapy
Ultragenyx and partner GeneTx have been given the go-ahead to up the dose in a phase 1/2 Angelman syndrome trial of antisense treatment GTX-102.
Annalee Armstrong
Jan 5, 2022 11:11am
Takeda stops narcolepsy clinical trials because of safety signal
Oct 6, 2021 4:45am
Acorda dumps $363M Parkinson’s drug after patient deaths
Nov 20, 2017 8:34am
Theravance COPD drug clears safety study, setting up NDA
Jul 20, 2017 6:44am
Juno ditches lead CAR-T program following patient deaths
Mar 2, 2017 4:03am
EMA updates first-in-human trial guidance
Nov 16, 2016 12:10pm